Patent · US Expired

Therapeutic use for glycine

US6281244A · kind A · utility

17Cited by

6References

4Claims

0Family size

Assignee

Novartis Nutrition AG · CH

Inventors

Heinz Schneider · Düren, DE
Ronald G. Thurman · Chapel Hill, US
Nigel Cook · Lacombe, CA

Key dates

Filing date	May 18, 1998
Grant date	Aug 28, 2001
Priority date	—
Expiry date	May 18, 2018

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K45/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Glycine is indicated to prevent or treat acute or chronic graft rejection, optionally in combination with an immunosuppressant or an immunomodulating agent.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.